Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rapid Micro Biosystems (RPID) EBT (2020 - 2025)

Rapid Micro Biosystems' EBT history spans 6 years, with the latest figure at -$11.5 million for Q3 2025.

  • For Q3 2025, EBT fell 1.65% year-over-year to -$11.5 million; the TTM value through Sep 2025 reached -$44.3 million, up 8.44%, while the annual FY2024 figure was -$46.9 million, 10.62% up from the prior year.
  • EBT for Q3 2025 was -$11.5 million at Rapid Micro Biosystems, up from -$11.8 million in the prior quarter.
  • Across five years, EBT topped out at -$9.7 million in Q4 2024 and bottomed at -$25.0 million in Q3 2021.
  • The 5-year median for EBT is -$13.4 million (2023), against an average of -$14.1 million.
  • The largest annual shift saw EBT plummeted 195.64% in 2021 before it surged 34.59% in 2022.
  • A 5-year view of EBT shows it stood at -$14.6 million in 2021, then decreased by 12.83% to -$16.4 million in 2022, then skyrocketed by 32.09% to -$11.2 million in 2023, then increased by 13.34% to -$9.7 million in 2024, then dropped by 18.83% to -$11.5 million in 2025.
  • Per Business Quant, the three most recent readings for RPID's EBT are -$11.5 million (Q3 2025), -$11.8 million (Q2 2025), and -$11.3 million (Q1 2025).